Status:
COMPLETED
An Open-Label Trial of Donepezil in Fragile X Syndrome
Lead Sponsor:
Stanford University
Conditions:
Fragile X Syndrome
Eligibility:
All Genders
14+ years
Phase:
PHASE1
Brief Summary
Fragile X syndrome is the most common known inherited cause of neurodevelopmental disability. Functional magnetic resonance imaging (fMRI) studies from our laboratory indicate that specific brain regi...
Detailed Description
Fragile X syndrome is the most common genetically inherited cause of neurodevelopmental disability in humans, affecting approximately 1:2000 to 4000 live births. Affected individuals have significant,...
Eligibility Criteria
Inclusion
- Confirmed genetic diagnosis of fragile X syndrome
- 2\. Age e 14
- 3\. Verbal IQ e 60
Exclusion
- Currently taking any anticholinergic medications, tricyclic antidepressant medications, or diphenhydramine.
- 2\. Presence of cardiac disease or bradycardia (\< 60 beats/minute) at initial evaluation.
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00220584
Start Date
July 1 2005
End Date
July 1 2009
Last Update
December 13 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305